Witnessing the stock’s movement on the chart, on March 16, 2023, Cytek Biosciences Inc. (NASDAQ: CTKB) had a quiet start as it plunged -1.44% to $9.56. During the day, the stock rose to $9.78 and sunk to $9.44 before settling in for the price of $9.70 at the close. Taking a more long-term approach, CTKB posted a 52-week range of $7.38-$16.05.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Nevertheless, stock’s Earnings Per Share (EPS) this year is 40.00%. This publicly-traded company’s shares outstanding now amounts to $135.02 million, simultaneously with a float of $111.55 million. The organization now has a market capitalization sitting at $1.33 billion. At the time of writing, stock’s 50-day Moving Average stood at $11.17, while the 200-day Moving Average is $12.38.
Let’s gauge the efficiency of the firm, which has a total of 583 employees. For the Profitability, stocks gross margin was +61.92, operating margin was -0.73 and Pretax Margin of +0.77.
Cytek Biosciences Inc. (CTKB) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Medical Devices industry. Cytek Biosciences Inc.’s current insider ownership accounts for 11.80%, in contrast to 53.10% institutional ownership. According to the most recent insider trade that took place on Mar 07, this organization’s President and CEO sold 20,000 shares at the rate of 10.13, making the entire transaction reach 202,600 in total value, affecting insider ownership by 7,704,439. Preceding that transaction, on Feb 21, Company’s Chief Technology Officer sold 20,000 for 10.94, making the whole transaction’s value amount to 218,800. This particular insider is now the holder of 7,926,053 in total.
Cytek Biosciences Inc. (CTKB) Earnings and Revenue Records
This company achieved a net margin of +1.57 while generating a return on equity of 0.62.
Cytek Biosciences Inc.’s EPS increase for this current 12-month fiscal period is 40.00% and is forecasted to reach 0.33 in the upcoming year.
Cytek Biosciences Inc. (NASDAQ: CTKB) Trading Performance Indicators
Let’s observe the current performance indicators for Cytek Biosciences Inc. (CTKB). It’s Quick Ratio in the last reported quarter now stands at 8.30. The Stock has managed to achieve an average true range (ATR) of 0.65. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 8.13.
In the same vein, CTKB’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.02, a figure that is expected to reach 0.03 in the next quarter, and analysts are predicting that it will be 0.33 at the market close of one year from today.
Technical Analysis of Cytek Biosciences Inc. (CTKB)
Going through the that latest performance of [Cytek Biosciences Inc., CTKB]. Its last 5-days volume of 0.95 million indicated improvement to the volume of 0.72 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 36.46% While, its Average True Range was 0.63.
Raw Stochastic average of Cytek Biosciences Inc. (CTKB) in the period of the previous 100 days is set at 8.84%, which indicates a major fall in contrast to 26.24% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 67.53% that was higher than 54.93% volatility it exhibited in the past 100-days period.